References
- Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clinical Cancer Research 2005; 11: 5935–5941
- Dudley RA, Edwards P, Ekins RP, Finney DJ, McKenzie IG, Raab GM, Rodbard D, Rodgers RP. Guidelines for immunoassay data processing. Clinical Chemistry 1985; 31: 1264–1271
- Feng XH, Lin X, Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-b. EMBO Journal 2000; 19: 5178–5193
- Goldsby RA, Kindt TJ, Osborne BA. Kuby Immunology. W.H. Freeman and Company, New York 2000
- Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD protein in TGF-b signaling pathways. Nature 1996; 383: 832–836
- Lawrence LW. The phagocytic leukocytes – morphology, kinetics, and function. Clinical Hematology: Principles, Procedures, Correlations, CA Lotspeich-Steininger, EA Stiene-Martin, JA Koepke. J.B. Lippincott Publishers, Philadelphia 1992; 292–302
- Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceutical Research 2006; 23: 312–328
- Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology 2005; 23: 5281–5293
- Massague J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 1996; 85: 947–950
- Massague J, Chen YG. Controlling TGF-b signaling. Genes & Development 2000; 14: 627–644
- Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-b2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investigative Ophthalmology & Visual Science 2003; 44: 3394–3401
- Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, et al. TGF-b receptor-mediated signaling through Smad2, Smad3 and Smad4. EMBO Journal 1997; 16: 5353–5362
- Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G, Hidalgo M. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clinical Cancer Research 2003; 9: 2887–2892
- Qing J, Zhang Y, Derynck R. Structural and functional characterization of the transforming growth factor-b-induced Smad3/c-Jun transcriptional cooperativity. Journal of Biological Chemistry 2000; 275: 38802–38812
- Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P. Targeted tumour therapy with the TGF-b2 antisense compound AP 12009. Cytokine Growth Factor Review 2006; 17: 129–139
- Shi Y, Massague J. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 2003; 113: 685–700
- Stopa M, Anhuf D, Terstegen L, Gatsios P, Gressner AM, Dooley S. Participation of Smad2, Smad3, and Smad4 in transforming growth factor b (TGF-b)-induced activation of Smad7. The TGF-b response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. Journal of Biological Chemistry 2000; 275: 29308–29317
- Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U and others. 2004. SD-208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Research 64:7954–7961.
- Wick W, Naumann U, Weller M. Transforming growth factor-b: a molecular target for the future therapy of glioblastoma. Current Pharmaceutical Design 2006; 12: 341–349
- Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang X-F, Massague J. TGFβ signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003–1014
- Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-b Receptor. Nature 1994; 370: 341–347
- Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-b signaling inhibitors for cancer therapy. Nature Review Drug Discovery 2004; 3: 1011–1022
- Zhang Y, Feng X-H, Wu R-Y, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-b response. Nature 1996; 383: 168–172